STAT+: New startup to test psychedelic-like drug against Parkinson’s symptom

STAT+ is reporting that a new startup plans to test a psychedelic-like drug against a Parkinson’s symptom. The item appears in STAT’s biotech newsletter/roundup, which also flags that the FDA’s new hiring push is hitting complications and mentions mice with human-esque or half-human brains.

Because the article is exclusive to STAT+ subscribers, the excerpt does not identify the startup, the specific Parkinson’s symptom, the drug, or the trial design. The title indicates an early-stage effort to bring a psychedelic-like compound into Parkinson’s research, adding to the emerging psychedelics-for-neurology sector. The roundup framing suggests the FDA hiring and human-mouse brain items are separate biotech news briefs rather than part of the same study.